Neha Krishnamohan Net Worth

Ms. Neha Krishnamohan biography

Neha Krishnamohan is the CFO, Principal Accounting Officer and Exec. VP of Corp. Devel. at Kinnate Biopharma.

What is the salary of Ms Krishnamohan?

As the CFO、 Principal Accounting Officer and Exec. VP of Corp. Devel. of Kinnate Biopharma, the total compensation of Ms Krishnamohan at Kinnate Biopharma is 459,520$. There are 2 executives at Kinnate Biopharma getting paid more, with Nima Farzan M.B.A. having the highest compensation of 647,291$.

How old is Ms Krishnamohan?

Ms Krishnamohan is 34, she's been the CFO、 Principal Accounting Officer and Exec. VP of Corp. Devel. of Kinnate Biopharma since . There are 5 older and no younger executives at Kinnate Biopharma. The oldest executive at Kinnate Biopharma Inc. is Dr. Richard Thomas Williams MBBS, Ph.D., 52, who is the Chief Medical Officer.

What's Ms Krishnamohan's mailing address?

Neha's mailing address filed with the SEC is C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361.

Insiders trading at Kinnate Biopharma

Over the last 4 years, insiders at Kinnate Biopharma have traded over 0$ worth of Kinnate Biopharma stock and bought 12,223,600 units worth 79,803,534$ . The most active insiders traders include Carl L Gordon、Advisors Llc Orbi Med Capit...、Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of 2,699,377$. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth 4,984,000$.

What does Kinnate Biopharma do?

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Kinnate Biopharma executives and stock owners

Kinnate Biopharma executives and other stock owners filed with the SEC include:

• Nima Farzan M.B.A.,
  Pres, CEO & Director
• Mark A. Meltz,
  COO, Gen. Counsel, Treasurer & Sec.
• Neha Krishnamohan,
  CFO, Principal Accounting Officer and Exec. VP of Corp. Devel.
• Dr. Eric Anthony Murphy Ph.D.,
  Chief Scientific Officer
• Jason Hampson M.D.,
  VP and Head of Regulatory Affairs & Quality
• Priyanka Shah,
  VP of Investor Relations & Communications
• Ken Kobayashi M.D.,
  Sr. VP of Clinical Devel.
• Jason Hampson,
  VP & Head of Regulatory Affairs
• Barbara Warren,
  VP of People & Culture
• Eric Martin Ph.D.,
  Sr. VP of Translational Medicine
• Dr. Robert Kania Ph.D.,
  Sr. VP of Drug Discovery
• Dr. Richard Thomas Williams MBBS, Ph.D.,
  Chief Medical Officer
• Nima Farzan,
  Pres, CEO & Director
• Capital Management Iv, Llc ...,
  
• Eric Anthony Murphy,
  Chief Scientific Officer
• Helen Sabzevari,
  
• Alsup Laurie Smaldone,
  
• James B. Tananbaum,
  
• Dean J Mitchell,
  
• Keith T. Flaherty,
  
• Advisors Llc Orbi Med Capit...,
  
• Advisors Llc Orbi Med Capit...,
  
• Michael E Rome,
  
• Melissa B, Epperly,
  
• Carl L Gordon,
  Director
• Capital Management Iv, Llc ...,
  
• Advisors Llc Orbi Med Capit...,
  
• Jill De Simone,
  
• Neha Krishnamohan,
  CHIEF FINANCIAL OFFICER
• Mark A Meltz,
  COO GENERAL COUNSEL SECRETARY
• Richard Thomas Williams,
  CHIEF MEDICAL OFFICER
• Nima Farzan,
  CHIEF EXECUTIVE OFFICER